Crossmark

Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease

Crossref DOI link: https://doi.org/10.1186/s13063-022-06132-z

Published Online: 2022-04-21

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gallagher, Hugh

Dumbleton, Jennifer

Maishman, Tom

Whitehead, Amy

Moore, Michael V.

Fuat, Ahmet

Fitzmaurice, David

Henderson, Robert A.

Lord, Joanne

Griffith, Kathryn E.

Stevens, Paul

Taal, Maarten W.

Stevenson, Diane

Fraser, Simon D.

Lown, Mark

Hawkey, Christopher J.

Roderick, Paul J.
Funding

Funding for this research was provided by:

Health Technology Assessment Programme (HTA Project: 16/31/127)

British Heart Foundation (SP/17/14/33355)
License Information

Text and Data Mining valid from 2022-04-21

Version of Record valid from 2022-04-21
More Information

Article History

Received: 26 May 2021

Accepted: 28 February 2022

First Online: 21 April 2022

Declarations

:

: The study received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) (Reference 16730/0223/001-0001) on 21st September 2018 and a favourable opinion from the East Midlands - Leicester Central Research Ethics Committee (REC) (Reference 18/EM/0248) on 9th October 2018. Health Research Authority (HRA) and Health and Care Research Wales (HCRW) Approval was granted on 15th October 2018.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below